Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 75 clinical trials
Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC neoSCORE

This is a Phase 2, prospective, randomized, open-Label, single-center international study that assesses the efficacy and safety of neoadjuvant therapy with different cycles of sintilimab combined with chemotherapy for resectable NSCLC. This trial will also explore the biomarkers of neoadjuvant immunochemotherapy.

proteinuria
transient ischemic attack
granulocyte colony stimulating factor
adjuvant therapy
interstitial lung disease
  • 0 views
  • 19 Feb, 2024
A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer

This study will evaluate the efficacy, safety, pharmacokinetics, immunogenicity and biomarkers of RO7198457 plus atezolizumab compared with atezolizumab alone in patients with Stage II-III non-small cell lung cancer (NSCLC) who are circulating tumor DNA (ctDNA) positive following surgical resection and have received standard-of-care adjuvant platinum-doublet chemotherapy.

hiv test
small cell lung cancer
immunomodulators
cancer
ct scan
  • 0 views
  • 19 Feb, 2024
A081801 / RLUN20119 / ALCHEMIST-IO (ACCIO) / Yuhchyau Chen  

Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB IIIA or IIIB non-small cell lung cancer.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

An ascending dose study in patients with solid tumors to evaluate the safety, tolerability, pharmacodynamics and efficacy of APG-1387 in combination with toripalimab. A phase II study of 3 cohorts will be included.

liver metastasis
brain metastasis
toripalimab
immunohistochemistry
growth factor
  • 0 views
  • 19 Feb, 2024
A Study of ADRX-0405 in Subjects with Select Advanced Solid Tumors

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0405 in patients with select advanced solid tumors.

  • 0 views
  • 02 Dec, 2024
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations

This is a Phase 1 study of JSI-1187 as monotherapy and in combination with dabrafenib for the treatment of advanced solid tumors with MAPK pathway mutations, including mutations that cause MAPK pathway hyperactivation.

mek inhibitor
liver metastasis
BRAF
ras-gap
gene fusion
  • 0 views
  • 19 Feb, 2024
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

targeted therapy
cisplatin
stage iv non-small cell lung cancer
adjuvant therapy
pulmonary function tests
  • 0 views
  • 19 Feb, 2024
SAR408701 Versus Docetaxel in Previously Treated Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients

Primary Objectives: Study is designed with two primary endpoints that will be analyzed on randomized participants at the time of the cutoff date for each given analysis (progressive free survival [PFS] and overall survival [OS]). Study success is defined either on PFS or OS The primary objective is to determine …

small cell lung cancer
metastasis
stage iv non-small cell lung cancer
measurable disease
squamous nsclc (non-small cell lung cancer)
  • 0 views
  • 19 Feb, 2024
  • 169 locations
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer ALCHEMIST Chemo-IO Study

The purpose of this trial is to find out if the addition of pembrolizumab to usual chemotherapy is better or worse than usual chemotherapy alone for non-small cell lung cancer.

monoclonal antibodies
cisplatin
immunohistochemistry
stage iiia lung squamous cell carcinoma ajcc v7
HIV Infection
  • 0 views
  • 19 Feb, 2024
cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation

The objective is to screen and monitor the efficacy of cfDNA methylation in patients with stage I lung cancer after ablation, to compare the similarities and differences of cfDNA methylation between surgical treatment and ablation in patients with stage I lung cancer, and to look for new indicators to assess …

cfdna
ct scan chest
lung cancer
chest ct
cancer
  • 0 views
  • 19 Feb, 2024